Eliem Therapeutics Inc ELYM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ELYM is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm
-
Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN
-
ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders
-
Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself
Trading Information
- Previous Close Price
- $3.39
- Day Range
- $3.32–4.16
- 52-Week Range
- $2.34–5.19
- Bid/Ask
- $3.88 / $4.07
- Market Cap
- $110.32 Mil
- Volume/Avg
- 580,221 / 749,683
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.eliemtx.com
Comparables
Valuation
|
Metric
|
ELYM
|
ICVX
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.94 | 3.30 | 3.57 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ELYM
ICVX
EWTX
Financial Strength
|
Metric
|
ELYM
|
ICVX
|
EWTX
|
|---|---|---|---|
Quick Ratio | 38.41 | 17.59 | 18.98 |
Current Ratio | 38.92 | 18.06 | 19.50 |
Interest Coverage | — | — | — |
Quick Ratio
ELYM
ICVX
EWTX
Profitability
|
Metric
|
ELYM
|
ICVX
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −18.81% | −29.30% | −24.36% |
Return on Equity (Normalized) | −19.50% | −31.87% | −25.87% |
Return on Invested Capital (Normalized) | −23.41% | −34.69% | −29.82% |
Return on Assets
ELYM
ICVX
EWTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xzvjlffns | Vlckd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vckqqrj | Fbkzvf | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yltfgfvc | Hyhqz | $97.8 Bil | |
MRNA
| Moderna Inc | Xfllnbv | Nbjd | $41.3 Bil | |
ARGX
| argenx SE ADR | Jpglcxjm | Jrnl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gwlkqzqd | Vcyv | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cffrdjr | Mdfvd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nvbxgkfg | Znbjfp | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mycxkcvvt | Ljfnl | $12.5 Bil | |
INCY
| Incyte Corp | Lybbwhwlc | Kdgvn | $11.6 Bil |